Idiopathic hypereosinophilic syndrome (HES) characterized by unexplained and persistent hypereosinophilia is heterogeneous and comprises several entities: a myeloproliferative form where myeloid lineages are involved with the interstitial chromosome 4q12 deletion leading to fusion between FIP1L1 and PDGFRA genes, the latter acquiring increased tyrosine kinase activity. And a lymphocytic variant, where hypereosinophilia is secondary to a primitive T lymphoid disorder demonstrated by the presence of a circulating T-cell clone. We performed molecular characterization of HES in 35 patients with normal karyotype by conventional cytogenetic analysis. TCRc gene rearrangements suggesting T clonality were seen in 11 (31%) patients, and FIP1L1-PDGFRA by RT-PCR in six (17%) of 35 patients, who showed no evidence of T-cell clonality. An elevated serum tryptase level was observed in FIP1L1-PDGFRA-positive patients responding to imatinib, whereas serum IL-5 levels were not elevated in T-cell associated hypereosinophilia. Sequencing FIP1L1-PDGFRA revealed scattered breakpoints in FIP1L1-exons (10-13), whereas breakpoints were restricted to exon 12 of PDGFRA. In the 29 patients without FIP1L1-PDGFRA, no activating mutation of PDGFRA/ PDGFRB was detected; however; one patient responded to imatinib. FISH analysis of the 4q12 deletion was concordant with FIP1L1-PDGFRA RT-PCR data. Further investigation of the nature of FIP1L1-PDGFRA affected cells will improve the classification of HES.
Introduction
A sustained and unexplained elevated eosinophil count (more than 1500/mm 3 for more than 6 months) characterizes hypereosinophilic syndrome (HES), a rare heterogeneous group of diseases where tissue infiltration by eosinophils and release of cytotoxic and proinflammatory mediators lead to organ damage. Several categories can be identified in HES. The presence of clonal cytogenetic abnormalities, including the t(5;12)(q33;p13) and related translocations associated with fusion genes involving platelet-derived growth factor receptor B (PDGFRB) [1] [2] [3] [4] [5] in the myeloid lineage, categorizes a first subgroup of HES, often called chronic eosinophilic leukemia. In the absence of detectable cytogenetic abnormality, another subset of HES patients with chronic myelogenous leukemia (CML)-like features is designated as myeloproliferative variant of HES. In contrast, hypereosinophilia can also been driven by an abnormal population of cytokine-secreting T lymphocytes defining a pathogenically distinct disease with underlying primitive lymphoid disorder. 6 Treatment of HES attempts to limit organ damage by controlling the eosinophil count, but the disease is usually fatal. It was recently reported that some patients with HES responded to imatinib mesylate, a tyrosine-kinase (TK) inhibitor effective in the treatment of CML but also of other chronic myeloid disorders associated with activation by translocations of C-ABL, PDGFRA or PDGFRB genes. 7 Activating mutations (deletions, insertions or point mutations) have also recently been described as mutually exclusive oncogenic events in C-KIT or PDGFRA genes. 8 Juxtamembrane or activation loop regions of PDGFRA also seem to be hotspots for these molecular events. 9 In vitro, a single amino-acid substitution reported in the juxtamembrane region of PDGFRB (exon 11) is sufficient to constitutively activate this receptor. 10 All those observations highlight the role of PDGFR-TK-family activation by either gene translocations or by mutations as a common theme in human tumors, which could be responsive to imatinib. Hence, clinical response of some HES cases to imatinib 11 raises the possibility that some HES patients might have an activated TK in spite of the absence of detectable rearrangement by conventional cytogenetic analysis. Indeed, Cools et al 12 reported nine of the HES patients in the study with the interstitial 4q12 deletion leading to FIP1L1-PDGFRA (F/P) gene rearrangement. The F/P-generated gene encodes for an activated TK that can transform hematopoietic cells and is inhibited by imatinib. 12, 13 Thus, according to the World Health Organization classification, cases of HES with this acquired chromosomal cryptic abnormality are referred to as eosinophilic leukemia [12] [13] [14] [15] [16] with myeloproliferative features, an increased serum level of vitamin B 12 or tryptase and imatinib responsiveness. However, the F/P genotype could be related to the pathogenesis of a subset of systemic mast cell disease associated to eosinophila (SMCD-eos) lacking D816V C-KIT mutation, 17, 18 associated to ill-defined mast cells aggregates and responding to imatinib.
In this paper, we report molecular characterization of 35 HES patients with normal conventional cytogenetic analysis by assessment of the following: (1) T-cell-receptor gamma gene rearrangements (TCRg); (2) detection of F/P by FISH and/or RT-PCR; (3) serum tryptase levels; (4) serum IL-5 level; (5) screening for activating mutations in the juxtamembrane and TK regions of PDGFRA and PDGFRB genes (exons [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] .
Materials and methods

Patients
Diagnosis of HES was based on three criteria: 19 (1) persistent eosinophilia 41500/mm 3 for longer than 6 months; (2) lack of evidence for parasitic, allergic or other known causes of eosinophilia; (3) signs and symptoms of organ involvement. Accordingly, 35 HES patients diagnosed in six French centers and with normal karyotype by conventional cytogenetic analysis were included in this study. Nine patients had clinical or hematological features of myeloproliferative syndrome (including palpable splenomegaly, neutrophilia, circulating myelocytes and/or erythroblasts, hyperplastic bone marrow, myelofibrosis); four patients had recurrent diarrhea with documented intestinal eosinophilic infiltration; and one patient presented dermatitis. No patient presented mast cell proliferation after May GiemsaGrü ndwald (MGG)-staining of smears for bone marrow smears.
No patient received imatinib at the time of study, but nine patients were receiving imatinib at a dose of 100-200 mg/day at the end of the study. Clinical and biological findings are listed in Table 1 .
Written informed consent from all patients was obtained for prospective clinical investigations and biological specimen collection.
Assay of serum tryptase level (UniCAP Tryptase fluoroenzymeimmunoassay, Pharmacia Diagnostics, Uppsala, Sweden) and serum IL-5 level (Immunotech IL-5 enzyme immunoassay IM1983/1984, Beckman Coulter, Inc., Fullerton, CA, USA) were performed according to the manufacturer's recommendations for 23 available patients.
TCRg gene rearrangement analysis
Genomic DNA was extracted from 10 6 PBMCs using QIAmp DNA minikit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. DNA quantity was measured by ultraviolet spectrofluorometry. Analysis of the junctional sequence of TCRg rearrangements (VI-J1J2; VI-JP1.2; V9-J1J2; V9-JP1.2; V10-J1J2; V10-JP1.2; V11-J1J2; V11-JP1.2) was performed on 50 ng DNA as previously described. 20 The presence of clonality was assessed from the pattern observed both by polyacrylamide gel electrophoresis and by fragment analysis using the CEQ8000 Beckman Genetic Analysis System and the Fragment Analysis software (V.5.0).
FIP1L1-PDGFRA RT-PCR analysis
Total RNA was extracted from 10 6 PBMCs using Trizol reagent (Life Technologies, UK), according to the manufacturer's instructions. cDNA synthesis and RT-PCR were performed from 1 mg of total RNA using MMLV reverse transcriptase with random hexamer primers (Pharmacia, Uppsala, Sweden). Control RT-PCR of a standard reference TBP gene was performed by quantitative RT-PCR procedure as previously described. 21 The F/P fusion transcript was then detected by nested PCR as described by Cools et al.
12
FISH analysis of the 4q12 deletion
Detection of 4q12 deletion was performed by a two-color FISH assay on metaphases from bone marrow cells or interphase nuclei from blood cells using BAC probes kindly provided by Dr M Rocchi (www.biologia.unitba.it/rmc). BAC probes were complementary for the 5 0 end of FIP1L1 (177B4; 53.336.303d), the 3 0 end of PGFRA and C-KIT (177J6; 56.149.025) and the interstitial region (367N1; 54.726.220). BAC DNA was isolated from 1.5 ml cultures using standard minipreps protocol, labeled by nick translation (Nick translation kit, Vysis, Downer Grove, IL, USA) with spectrum orange (spectrum orange dUTP, Vysis,) for 177B4 and 177J6 and spectrum green (spectrum green dUTP, Vysis) for 367N1 and hybridized by pair (177J6/367N1 or 177B4/367N1) following standard procedures. For each probe, the specificity and sensitivity were assessed on normal and abnormal metaphases. The positivity threshold on nuclei (one fusion signal and one red signal) was 1.78% (mean values þ 2 standard deviations obtained from five normal controls and two disease samples) with 367N1/177J6 probes. For each slide, 500 nuclei were analyzed by two different observers.
Sequence analysis of PDGFRA, PDGFRB and FIP1L1-PDGFRA Exons 11-20 of PDGRFA and PDGFRB genes were amplified from 300 ng DNA using primer sequences and annealing conditions listed in Table 2 . For F/P, sequence was performed on RT-PCR products using previously described nested primers. 12 After purification on QIAquick PCR purification column (Qiagen, Hilden, Germany), RT-PCR fragments were sequenced following ABI protocol for Taq-Dye Terminator Sequencing on an automated ABI377 sequencer. Sequences were analyzed with Sequence Analysis software V.3.3 and Sequence Navigator software V.1.0.1 (Applera). Sequencing was performed on both strands.
Statistical analysis
Correlation between serum IL-5 or tryptase levels and molecular findings (i.e. lack or presence of TCRg rearrangements or F/P transcript) was assessed using the Mann-Whitney test.
Results
Molecular characterization of HES
Of the 35 HES patients, 34 were studied for TCRg rearrangement; and 11 (31%) of them had one to three clonal TCRg rearrangements ( Table 1) .
Six of the 35 patients (17% , Table 1 ) expressed the F/P deletion by RT-PCR. Sequencing of the resulting F/P fusion revealed breakpoints scattered between FIP1L1 exons 10-13 (according to the European LeukemiaNet numbering), whereas breakpoints in PDGFRA gene were restricted to a small region in exon 12. Breakpoints in FIP1L1 were located in intron 10 (patients no. 20, 5, 26); in exon 11 (patient no. 1), in exon 12 (patient no. 22) and in exon 13 (patient no. 32) (Figure 1a) . Despite different breakpoints, all F/P deletions were in frame. The resulting sequences of fusion proteins are presented in Figure 1b .
Five of the 29 patients (17%) tested by FISH analysis had 4q12 deletion ( Figure 2) . In those patients, loss of signal corresponding to the interstitial deleted region on interphase nuclei from 
C Roche-Lestienne et al blood cells or metaphases from bone marrow confirmed F/P RT-PCR results ( Table 2 ). The last patient with the F/P fusion by RT-PCR was not analyzed by FISH, and none of the patients without F/P fusion by RT-PCR had a positive FISH finding for 4q12 deletion.
With FISH analysis, we observed a lower percentage of F/P positive nuclei compared to the eosinophil count in MGGstained blood smears from peripheral blood (patients no. 20, 22, 32; Table 1 ).
Screening for mutations in juxtamembrane or TK region was performed by direct sequencing in all cases lacking F/P. No mutation was detected by this method (data not shown). Therefore, 18 patients (51%) in this study had neither F/P fusion nor clonal T-cell rearrangement.
Serum IL-5 and serum tryptase levels
Serum IL-5 and serum tryptase levels were measured in 23 patients (Table 1 ). There was no statistically significant difference in the serum IL-5 levels in patients with TCRgassociated hypereosiniphilia compared to others, whereas a significantly elevated serum tryptase level was observed in F/Ppositive patients compared to F/P-negative patients with hypereosinophilia (P ¼ 0.47 and 0.006, respectively, MannWhitney test).
Response to imatinib
At the end of the screening period, nine patients received imatinib (100-200 mg daily). All patients with the F/P deletion reached complete hematological remission with imatinib within the first month of therapy and F/P monitoring by RT-PCR revealed lack of positive signal after 2 months of therapy (data not shown). Another patient (no. 16) achieved complete hematological remission under imatinib, although no F/P deletion was detected ( Table 2) .
Discussion
Mature eosinophils are released into the blood stream and migrate to peripheral tissues. In the absence of survival cytokines such as IL-3, IL-5 or GM-CSF, they rapidly undergo apoptosis. Therefore, overproduction of one of those factors could be sufficient to induce hypereosinophilia. The clonal expansion of an IL5-producing T-cell population has been demonstrated in T-cell associated hypereosinophilia and extensive characterization of these circulating T cells showed an aberrant phenotype. 6, 22, 23 In one study, eight of 60 HES patients (13%) demonstrated clonal rearrangement of a/b or d/g T-cell receptor genes, 23 and it was currently unknown whether a subset of T-cell associated hypereosinophilia can also exhibit the 4q12 deletion. In our study, we found a high occurrence of Table 2 Primers sequences for amplification of PDGFRA and PDGFRB exons and corresponding annealing temperatures --------------------------------------------------------------------------------------- -gccgaagactgtacta---------------------------------------------------------------------- T-cell related hypereosinophilia (31%), which we believe is representative since only one patient of the study had been recruited from a dermatology clinic. In contrast to Tefferi et al, 24 who recently reported in a purified T lymphocyte population F/P-positive cells by FISH in one of three analyzed patients with SMCD-eos, none of our patients had F/P deletion, suggesting that it may be here restricted to the myeloid lineage. No higher serum IL-5 level was found in T-cell associated hypereosinophilia as compared to other patients in our study. Extensive analysis of cytokine and chemokine profiles as well as detection of aberrant-T cells could therefore improve the characterization of the HES in these patients.
In our series, six patients (17%) exhibited the F/P fusion by RT-PCR and FISH analysis. This incidence is lower than previously described 1, 12, [15] [16] [17] [18] 25 (30-60%). In agreement with previous reports, 16, 25 we found a significantly elevated serum tryptase level in all of F/P deleted patients. In recent reports, a myeloproliferative variant of HES associated with elevated serum tryptase and vitamin B 12 , hyperplasia of bone marrow dysplastic mast cells and F/P fusion has been reported as different from typical systemic mastocytosis, 15 and F/P-positive patients reported by Pardanani et al 17, 18 have been re-classified as SMCD-eos. Thus, the difference between F/P-positive HES and SMCD-eos remains to be established. Since the bone marrow tryptase immunostaining was not been performed here, we could not exclude the presence of some F/P-positive SMCDeos case in our study.
Sequencing of all six F/P fusion genes revealed six different breakpoints in FIP1L1 distributed in exons 10-13, whereas breakpoints were restricted to exon 12 of PDGFRA, confirming previous studies. The mechanism of TK activation in FIP1L1-PDGFRA fusion is currently not well understood but PDGFRA breakpoints seems to always occur in the juxtamembrane region, which is known to have an autoinhibitory function. Therefore, disruption of exon 12 of PDGFRA gene could be an activating event, whereas the remaining FIPL1 sequence could preserve homodimerization required for functional TK. In the remaining 18 patients without F/P deletion or TCR clonality, we conducted a wide screening for mutations in the juxtamembrane and TK domains of PDGFRA and PDGFRB genes, but no mutation was detected.
In the present study, clinical improvement and complete hematological remission under imatinib was observed in all six F/P patients, confirming previous results. By contrast, only one of the five treated F/P-negative patients (no. 16) responded to imatinib, which may be indicative of a deregulated TK activity in this patient, although this remains putative. Molecular monitoring of residual disease to evaluate response (and resistance) in F/P-positive imatinib-treated patients is useful. In our hands, however, we previously showed low sensitivity (10 À3 ) of the assay in one patient (no. 1) of the study. 26 Therefore, 'molecular remission' by RT-PCR with F/P primer sequences according to Cools's protocol 12 should be considered with caution, and efforts should be made to improve assay sensitivity.
Using imatinib, Klion et al 15 observed rapid disappearance of dysplastic mast cells and eosinophils, suggesting that both granulocytic lineages may arise from the primary F/P-deleted cell in those cases. However, demonstration of the clonality of these cells still has to be made, as reactive polyclonal eosinophilia can be observed. In one SMCD-eos patient described by Pardanani et al, 17 the F/P fusion was detected by FISH in enriched eosinophil and neutrophil fractions from peripheral blood mononuclear cells, and a recent report supported the early stem cell origin of F/P in HES. 24 At first sight, one could assume that different phenotypes could result from the same abnormality, depending of the cell type affected by the F/P fusion. In our study, F/P deleted cells were observed by FISH analyses in a part of the eosinophils. This observation may suggest the coexistence of a nonleukemic eosinophilic population, maybe reactive trough mechanisms such as secretion of growth factors. We could not exclude that the difference seen between the percentage of 4q12 deleted cells detected by FISH and the percentage of eosinophils on blood smears was overestimated (due to technical difficulties), but we found a very low background of eosinophil autofluorescence on our slides, as shown in Figure 2 . Furthermore, since no deleted cells were observed in a CD16À purified fraction of eosinophils in one F/Ppositive patient before imatinib therapy (data not shown), we may suggest in this patient a F/P clonality restricted to lowdensity cells retained in the mononuclear cell layer (CMN) after density gradient separation, but further investigations of the CMN and CD16 þ /CD16À fractions in other HES patients should be performed to confirm this hypothesis. Of note is that variability in density of human peripheral blood eosinophils has been reported to be related to level and origin of hypereosinophilia. 27 Additional characterization of nature of F/P-positive cells is clearly need to improve the classification of hypereosinophilia.
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